Market Research Reports

  Global microbiome therapeutics market is expected to grow further in the coming years due to the continuous increase in awareness and need for better and safer treatment alternatives and the dominance of gastrointestinal (GI) and infectious diseases segment can be attributed to the existing dominance of microbiome therapeutics available for a variety of indications ranging from diarrhea and gut dysbiosis to skin disorders, cancer indications among others. The global microbiome therapeutics market which accounted for $306.3 million in 2021 is expected to reach $3,204 million by 2032, reporting a CAGR of 24.95% during the forecast period 2022-2032. The existing   microbiome therapeutics market    is favored by multiple factors, including the rising geriatric populations coupled with the increasing adoption of inorganic growth strategies by key players in the market. Impact of COVID-19 There were numerous consequences due to the COVID-19 pandemic, especially...

Microbiome is defined as the collective genomes of the microbes (composed of fungi, bacteria, bacteriophage, viruses, and protozoa) that live inside and on the body. Clinical studies on various microbiomes have been significantly growing during the past decade, owing to the considerable reduction in the cost of DNA sequencing, enabling the microbes in their complex mixture to be defined by their genome. Research findings have generated information about the role of the microorganism population in determining human health.  The microbiome is found to play a role in inflammatory bowel disease (IBD), allergies, and immune-oncology, among others.  Microbiome has become an attractive target for potential therapeutics owing to its extensive role in gastrointestinal and non-gastrointestinal diseases. However, there are challenges associated with microbiome research. Determining the cause-effect relationships and designing microbiome-based therapies that can attain effective results o...